Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

• US 9,938,353 B2
• Filed: 06/22/2012
• Issued: 04/10/2018
• Est. Priority Date: 06/24/2011
• Status: Active Grant

• Current Assignee: Konkuk University, The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: Dinarello, Charles, Crapo, James D, Kim, Soohyun
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US14/125,135
• Publication Number:
  US 20140341899A1
• Time in Patent Office: 2,118 Days
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 15/10 for impotence
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 39/00 General protective or antinoxious agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/8125 Alpha-1-antitrypsin
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/62 DNA sequences coding for fusion proteins

Abstract

Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

Claims

1. A nucleic acid construct comprising:

a polynucleotide encoding an alpha-1 antitrypsin (AAT) polypeptide fragment wherein the AAT polypeptide fragment consists of the polypeptide sequence represented by SEQ ID NO;

34;

a polynucleotide encoding a linker; and

a polynucleotide encoding an immunoglobulin Fc polypeptide of IgG2, IgG3, IgG4, or IgD.

3. An isolated vector comprising the nucleic acid construct of claim 1.

4. An isolated cell comprising the vector of claim 3.

2. A nucleic acid construct comprising the construct encoding the fusion polypeptide of SEQ ID NO:

48.

5. A nucleic acid construct comprising a polynucleotide encoding an alpha-1 antitrypsin (AAT) polypeptide fragment wherein the alpha-1 antitrypsin (AAT) polypeptide fragment consists of the polypeptide sequence represented by SEQ ID NO:

31, a polynucleotide encoding a linker; and

a polynucleotide encoding an immunoglobulin Fc polypeptide of IgG2, IgG3, IgG4, or IgD.

6. The nucleic acid construct of claim 5, wherein immunoglobulin Fc polypeptide is IgG4 Fc.